Latest Content

A recent study highlights lumateperone's effectiveness in preventing schizophrenia relapse, showcasing its potential for long-term treatment benefits.

Data presented at the ECNP Conference showed CT-155 has promise in reducing negative symptoms of schizophrenia.

New data indicates safety of seltorexant and its pharmacokinetics in treating adolescent depression, supporting its potential as an effective adjunct therapy.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

Esketamine nasal spray shows significant improvements in treatment-resistant depression, with effective dose management and minimal adverse effects in recent studies.

Explore the evolving significance of Indigenous People's Day and its impact on mental health, community healing, and historical recognition.

"They toil in a sterile field, pack produce on ice fast as death’s freedom allows..."

New research highlights lumateperone's effectiveness as an adjunctive treatment for major depressive disorder, improving depressive symptoms and sexual function.

Explore the complex neuropsychiatric symptoms of Huntington disease and the challenges in treatment and management for affected patients.

World Mental Health Day emphasizes the importance of mental health access during crises, urging professionals to prioritize their own well-being amidst challenges.

Sleep disruption undermines team coordination in sports, revealing its critical role in collective performance and strategic success.